FDA Approves IND Application for Immuron’s IMM-529 to Treat C. difficile Infection
I'm PortAI, I can summarize articles.
Immuron Limited has received FDA approval for its IND application for IMM-529, enabling a Phase 2 clinical trial for treating Clostridioides difficile infection (CDI). The drug, which uses antibodies from hyperimmune bovine colostrum, aims to prevent and treat CDI, including recurrent cases. The trial is set to begin in the first half of 2026. This announcement was made on November 05, 2025, and is for informational purposes only, not to be considered as financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments